Modern aspects in multidisciplinary thromboembolic prophylaxis. AMPLATZER Left Atrial Appendage data update
|
|
- Ami Oliver
- 5 years ago
- Views:
Transcription
1 Modern aspects in multidisciplinary thromboembolic prophylaxis AMPLATZER Left Atrial Appendage data update Igal Moarof, MD Interventional Cardiology Kantonsspital Aarau
2 Potential conflicts of interest Speaker s name: Igal Moarof I have the following potential conflicts of interest to report: Consultant for SJM / Abbott
3 AMPLATZER left atrial appendage occlusion Clinical Data ACP Initial EU Registry¹ N = 37 ACP EU Prospective Observational Study² N = 4 Amulet Global Observational Study4 N = 88 ACP Multicenter experience³ N = 47 AMPLATZER Amulet IDE LAA Occluder RCT N = >6 (ongoing) Physician-Driven Published Real-World Data N = > published papers (Pubmed search). Park, J. W., et al. (). LAA closure with AMPLATZER Cardiac Plug in atrial fibrillation - initial European experience. Catheterization and Cardiovascular Interventions, 77(5), Walsh, K. (, May). LAA closure with the AMPLATZER cardiac plug: results of the European post-market observational study. Presented at EuroPCR, Paris. 3. Tzikas, A., et al. (6). LAA occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention, (), Landmesser, U. et al.. 7. LAA occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study. EuroIntervention 7;3-online publish-ahead-of-print June 7
4 Multicenter Study Experience With the AMPLATZER Cardiac plug Single-arm multicenter clinical evaluation of ACP for stroke prevention in AF pts. Total patients,47 Number of centers Patient years follow-up,349 CHA DS -VASc (Mean) 4.5 HAS-BLED (Mean) 3. Age (Mean) 74.9 Prior stroke / TIA 37% Previous major bleeding 47% Taking OAC at time of implant 9.5% Concomitant procedures to LAAO.6% Tzikas, A. et al. (6). Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention, (), 7-79.
5 Multicenter Study Experience with the AMPLATZER Cardiac Plug Indication for LAAO in more than, patients: Previous major bleeding High bleed risk CAD and stenting Drug Interaction Stroke on Warfarin Previous minor bleeding Renal or hepatic disease Labile INR Risk of falls 9% 8% 7% 6% 5% 4% % 35% 47% % 5% % 5% % 5% 3% 35% 4% 45% 5% Tzikas, A. et al. (6). Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention, (), 7-79.
6 Multicenter Study Experience With the AMPLATZER Cardiac Plug 6% 4% Effectiveness in Stroke Reduction vs. Estimated 5,6% 6% Effectiveness in Bleeding Reduction vs. Estimated 4% 5,34% -59% - 6% % %,3% Estimated based on CHA DS -VASc score Observed rate in study % %,8% Estimated based on HAS-BLED score Observed rate in study Total Patients Total Patient Years CHA DS -VASc Score Total Patients Total Patient Years HAS-BLED Score Estimated Stroke Rate per CHA DS -VASc Actual Annual Stroke Rate (N strokes + TIA) Estimated Bleeding Rate per HAS-BLED Actual Annual Bleeding Rate (N major bleeds) 5.6%.3% (3) 5.34%.8% (8) Tzikas, A. et al. (6). Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention, (), 7-79.
7 TE rate [events/year] Expected and observed stroke rates in AMPLATZER LAA Occluders 9,6 8 8,6 7,7 7, ,8 58% 5% 58% 6,7 5,9 5,6 5,8 5,3 5% 75% 6% 68% 59% 6% 7% 66% 58% Expected* Observed,98,4,4,3,5 3,,3,3,, Walsh Kefer Lopez- Minguez Urena Chun Santoro Kebernik Tzikas Korsholm Berti Berti - Patients Patient years NR Strokes/TIAs TEreduction [%] 5% 58% 75% 6% N/A 68% 5% 59% 6% 7% 66% * Expected stroke rates are based on the patients CHADS or CHADSVASc scores.. Walsh et al. Presented at EuroPCR, Paris.. Kefer, J. et al. Acta Cardiolog. 368(6); López-Mínguez et al. Heart. 5;: Urena et al. JACC Cardiovascular Interventions, 3. 6, Chun et al. Heart Rhythm, 3, Santoro et al. EuroIntervention, 6. (), Kebernik et al. Cardiology and Therapy, 5. 4(), Tzikas et al. EuroIntervention, 6. (), Korsholm et al. EuroIntervention. 7;:75-8. Berti et al. Heart. 6;: Berti et al., Int J Cardiol. 7 Jul 6. pii: S67-573(7).
8 Reported by Procedural success and safety with AMPLATZER Cardiac Plug > patients* Nietlispach¹ Park² (Multi) Berti³ (Italian) Walsh 4 (Multiple) Santoro 5 (Spain) Tzikas 6 (Multiple) Lopez- Minguez 7 (Spain) Meerkin 8 (Israel) Betts 9 (UK) Berti () (Italian) Nielsen- Kudsk (Nordic) Enrollment period 8 /8 /9 /9 4/3 8/9 9/ /9 / /8 /3 3/9 3 NR 7/9 /4 /8-4/5 9 /5 CHADS NR NR NR.6 NR.8 3 (median) ±.4 - NR CHA DS -VASc (median) (median) - 4. ± ± Patients enrolled Successful device implantation Major peri-procedural complications Stroke/TIA MI / air embolism Device embolization Major tamponade/effusion Major bleeding Other 7 (97.5%) 7 (5.8%) 3 3 (96.4%) (7.3%) (96.7%) 4 (3.3%) 3 97 (96.6%) 6 (.9%) (95.5%) 4 (3.%) 3 9 (97.3%) 5 (4.97%) (94.6%) 9 (5.4%) 4 (%) (.%) 9 (95.%) 6 (4.8%) All studies include learning curve increased success rates and reduced complication rates with increasing operator experience. Procedures carried out according to IFU with Echocardiography and fluoroscopy. 585 (95.4%) 38 (6.%) 4 7 (97.%) 7 (4.%) 3.Nietlispach et al. Cath and Card Int., 3. 8, Park et al. Cath.and Card.Int.,. 77(5), Berti et al. J.American College of Cardiology: Card. Int. 4. 7, Walsh et al. Presented at EuroPCR, Paris. 5. Santoro et al. EuroIntervention, 6. (), Tzikas et al. EuroIntervention, 6. (), López-Minguez et al. Heart, 5., Meerkin et al. International Journal of Cardiology, 3. 68, Betts et al. Catheter Cardiovasc Interv. 6 Sep. [Epub ahead of print]. Berti et al. Int J Cardiol. 7 Jul 6. [Epub ahead of print]. Nielsen-Kudsk et al. EuroIntervention. 7 Jun ;3(3): doi:.444/eij-d-7-.
9
10 AMPLATZER Amulet Device Multicentre prospective real-world observational study Procedural and up to 3 month follow up Study and patient characteristics Enrollment,88 (6 centers, enrolled between June 5 and September 6) Age 75±8.5 years CHA DS -VASc 4.±.6 (64.9% CHA DS -VASc score 4) HASBLED 3.3±. (77.% HAS-BLED score 3) Follow up.4±.8 months. Indication General Anaesthesia 8.8% absolute or relative contraindication to LT OAC 7.4% previous major bleeding 56.5% Landmesser, U.,et al. EuroIntervention 7;3-online publish-ahead-of-print June 7
11 AMPLATZER Amulet Device Multicentre prospective real-world observational study Procedural and up to 3 month follow up Results Successful implantation 99% Closure < 3mm (follow up) 98.% First device choice 93.9% % 5% LAA Closure Rates 99,6% 98,% LAA closure defined by an independent echo core lab as absence of peri-device flow or- flow of < 3 mm jet into the LAA Implanting centers reported: 99.7% at implant and 99.4% at 3 months of patients had no leak or < 5mm. % LAA Closure (Implant) LAA Closure (-3 Month Visit) Landmesser, U.,et al. EuroIntervention 7;3-online publish-ahead-of-print June 7
12 AMPLATZER Amulet Device Multicentre prospective real-world observational study During Procedure and Index Hospitalization (CEC Adjudicated) Results Major AE 3.% Major bleeding: Pericardial effusion/tamponade Pericardiocentesis Surgery.4% (.%) (.9%) (.3%) Vascular complications.9% Death.% cardiac perforation cardiorespiratory arrest/shock Device embolization.% Landmesser, U.,et al. EuroIntervention 7;3-online publish-ahead-of-print June 7
13 AMPLATZER Amulet Device Multicentre prospective real-world observational study Procedural and up to 3 month follow up Post procedural medication (discharge) Single antiplatelet 3% Dual antiplatelet 54.3% Oral anticoagulation 8.9% No antithrombotic therapy % Device Associated Thrombus: Ten () cases of device on thrombus were reported through 9 days of implant. Represents.9% device on thrombus rate within 9 days of implants in all implanted patients in the study. ( out of 77 implant attempts) Represent.5% ( out of 673 echoes adjudicated by core lab) One patient had an ischemic stroke 8 days after detection of device thrombus. Landmesser, U.,et al. EuroIntervention 7;3-online publish-ahead-of-print June 7
14 Procedural success and safety of AMPLATZER Amulet LAA occluder > patients* Study Freixa Cruz² Abualsaud³ Bartoletti 4 Karczewski 5 Kleinecke 6 Landmesser 7 Aguirre 8 Enrollment period 7/ - 6/3 Mean stroke risk CHADS CHA DS -VASc NA 4.3 ±.7 4 NA 4.9 ±.3 /9 6/ /4 /5 NA 4(median) NA /4 8/5 3 5 NA 5. ±.8 6/5 9/6 NA 4.±.6 LAA occlusion attempted Successful device implantation Major peri-procedural complications Stroke TIA MI / coronary air embolism Device embolization Major tamponade//effusion Major bleeding Other Minor peri-procedural complications LAA closure success (% < 3mm leak) 4 (96%) (%) 3 (%) 39 (%) 34 (%) 49 (98%) 4 (retropharyngea l hematoma) 77 (99%) deaths (perforation and cardiac arrest) 3 (vascular) 5 ( vascular) (vascular) -3 mths: % Procedures performed with recommended echocardiographic and fluoroscopic Guidance 6 days: % Mean.4 mths: 96% Mean 89 ± 9 days 9.6% pts<5mm leak) 6 mths: % 6 weeks: % Mean.4±.8 mths: 98.%. Freixa X, et al. Int J Cardiol. 4 Jul ;74(3): Cruz-González, I. et al. Revista Española de Cardiología, 5. 68, Abualsaud, A. et al. J.Inv. Card., 6. 8, Bartoletti,S. et al. Heart 6;:A45-A Karczewski M. et al. Kardiochir Torakochirurgia Pol. 6 Jun;3(): Kleinecke C, et al. Cardiol J. 7 Feb 5. [Epub ahead of print] 7. Landmesser, U.,et al. EuroIntervention 7;3-online publish-ahead-of-print June 7 8. Aguirre et al. Catheter Cardiovasc Interv. 7 Aug 4. [Epub ahead of print] 6-9/6 3.8 ±. NA (%) 3 days: % <5mm
15 Aspirin alone for post-implant antithrombotic therapy Study and patient characteristics Results Enrollment CHADS-VASc 4.4±.6 HASBLED 4.±. Follow up Indication 7 patients March -March 5 Median.3 years 8% Bleeding indication Success % Complication rate Stroke risk Bleeding risk Device related thrombus 4.6% Annual risk of stroke reduced by 6% to predicted rate Annual risk of bleeding reduced by 57% /7 (.9%) had clopidogrel due to aspirin intolerance month post implant at 6 weeks managed with heparin At month follow up 6% patients were without any ASA or antithrombotic medication Conclusion Aspirin monotherapy is safe post LAAO with AMPLATZER LAAO Devices Korsholm K, et al. EuroIntervention. 6 Dec 5. [Epub ahead of print]
16
17 AMPLATZER Amulet Device Randomized control trial - ongoing Study Overview Objective Prospective, randomized, multi-center active control trial designed to evaluate the safety and effectiveness of the AMPLATZER Amulet Left Atrial Appendage Occluder (LAAO). The AMPLATZER Amulet is intended to reduce the risk of thromboembolism from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AF). To evaluate the safety and effectiveness of the AMPLATZER Amulet device by demonstrating that the device is non-inferior to the commercially available WATCHMAN left atrial appendage closure device (Control) in subjects with non-valvular AF. Endpoints Primary safety endpoint: o Composite of procedure-related complications, all cause death, major bleeding through months Primary effectiveness endpoint: o A composite of ischemic stroke or systemic embolism through 8 months Primary mechanism of action endpoint: o Device closure (defined as residual jet around the device <5mm) at the 45d visit Design Study Population Data Collection Status Ongoing Prospective, global, multi-center active control trial with : randomization to Amulet (Treatment) or WATCHMAN (Control), evaluating approximately >6 patients Patients aged 8 and older, with non-valvular atrial fibrillation (AF) who: Are at increased risk for stroke and systemic embolism based on CHADS and CHADS-VASc scores Are recommended for anticoagulation therapy Are deemed by their physician to be suitable for warfarin; and Have an appropriate rationale to seek a non-pharmacologic alternative to warfarin Baseline, Procedure, Discharge, Follow-up (45d, 6mo, mo, 8mo, 4mo and annually for 5 years) Testing/Assessments: TEE (baseline, 45d, mo), TTE (at discharge), medication assessment (all visits), MRI/CT (after suspected stroke/tia)
18 Summary AMPLATZER Left Atrial Appendage Occluders demonstrate experienced operators are able to achieve an implant success rate between 95% and %. AMPLATZER Left Atrial Appendage Occluders show there is an overall procedural complication rate of 4% or lower. The most common procedure-related safety event is pericardial effusion, occurring less frequently with increasing operator experience. Closure (<3mm jet at follow up) in more than 9% of patients. Longer-term follow-up results show stable and effective LAA occlusion over time and a reduction in stroke rate between approximately 6% and 75%, compared to the stroke incidence predicted by the CHADS or CHA DS -VASc score.
19 Conclusion Randomized control trials still lacking The majority of patients implanted according to European guidelines (Unable to tolerate OAC) results demonstrate: Percutaneous LAA occlusion is a feasible option for stroke reduction in AF patients at high risk for stroke who are contraindicated to long term oral anticoagulation Percutaneous LAA occlusion is a feasible option for stroke reduction in AF patients at high risk for stroke who have suffered a stroke despite OAC. LAA occlusion is also associated with markedly less major bleeding than OAC.
Continuing Cardiology Education
Continuing Cardiology Education REVIEW ARTICLE Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: indications diversity and future perspectives A. Tzikas 1 & T.
More informationDevices to Protect Against Stroke in Atrial Fibrillation
Devices to Protect Against Stroke in Atrial Fibrillation Jonathan C. Hsu, MD, MAS Associate Clinical Professor Division of Cardiology, Section of Cardiac Electrophysiology June 2, 2018 Disclosures Honoraria
More informationSURGICAL VS ELECTROPHYSIOLOGICAL INTERVENTIONS FOR CARDIAC ARRHYTHMIAS DEBATE 2: LAA CLOSURE IS BEST DONE WITH DEVICES
SURGICAL VS ELECTROPHYSIOLOGICAL INTERVENTIONS FOR CARDIAC ARRHYTHMIAS DEBATE 2: LAA CLOSURE IS BEST DONE WITH DEVICES Dr. Marco Barbierato Interventional Cardiology Cardio-Thoraco-Vascular Department
More informationAtrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?
Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently
More informationLeft Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE
Left Atrial Appendage Closure for Atrial Fibrillation 2015 UPDATE Adam Greenbaum, MD NCVH Detroit 2015-09-12 Disclosures Former proctor: SentreHEART Discussion may include the use of non-fda approved devices
More informationLeft Atrial Appendage Closure Devices. Atrial Fibrillation 10/11/2017
Left Atrial Appendage Closure Devices Emile Daoud, MD Chief, Cardiac Electrophysiology Wexner Medical Center, The Ohio State University Atrial Fibrillation 1 Adjusted Annual Stroke Risk Using CHA 2 DS
More informationLeft Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016
Left Atrial Appendage Closure: Moving Beyond Blood Thinners to Prevent Stroke in Atrial Fibrillation October 29, 2016 Jesse Jorgensen, MD, FACC Director, Cardiac Cath Lab, Greenville Health System Disclosures
More informationPrimary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion. Greg Francisco, MD, FACC
Primary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion Greg Francisco, MD, FACC DISCLOSURES None to declare Estimated 33.5million have AF worldwide (6-7million in
More informationOcclusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France
Occlusion de l'auricule gauche: Niche ou réel avenir? D Gras, MD, Nantes, France LAA Occlusion Is there a real future? Background Protect AF Trial Other Studies CAP, ASAP, Prevail Left Atrial Appendage
More informationTHINK OUTSIDE THE PILLBOX
WATCHMAN : A CLINICALLY PROVEN AND SAFE THERAPY FOR YOUR NVAF PATIENTS WATCHMAN reduces the risk of stroke in NVAF patients as effectively as warfarin WATCHMAN also reduces the long-term risk of bleeding
More informationLeft Atrial Appendage Closure
Left Atrial Appendage Closure Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org Risk Factors for Stroke From The Perspective
More informationAtrial fibrillation (AF), one of the
Hellenic J Cardiol 2013; 54: 408-412 Case Report Left Atrial Appendage Occlusion with the Amplatzer Amulet for Stroke Prevention in Atrial Fibrillation: The First Case in Greece Apostolos Tzikas, Lambros
More informationPercutaneous Epicardial LAA Closure: When Does it Make Sense?
Percutaneous Epicardial LAA Closure: When Does it Make Sense? Petr Neuzil, MD,PhD, FESC Professor of Medicine Cardiology department Na Homolce Hospital, Prague, Czechia petr.neuzil@gmail.com Disclosures
More informationManuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
More informationLeft-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Medical Policy Manual Surgery, Policy No. 195 Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Next Review: November 2019 Last Review: January 2019 Effective: February
More informationRole of cardiac imaging for catheterbased left atrial appendage closure
Role of cardiac imaging for catheterbased left atrial appendage closure Ana G. Almeida, MD, PhD Cardiology University Hospital Santa Maria, Lisbon Ana G. Almeida, MD, PhD, FESC University Hospital Santa
More informationPercutaneous Left Atrial appendage occlusion and anticoagulation therapy Nicolas Lellouche, MD, PhD
Percutaneous Left Atrial appendage occlusion and anticoagulation therapy Nicolas Lellouche, MD, PhD Fédération de Cardiologie Hôpital Henri Mondor Créteil Atrial Fibrillation is a major cause of Stroke
More informationPatients selection criteria for LAA occlusion. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Patients selection criteria for LAA occlusion Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Atrial Fibrillation The most common cardiac arrhythmia. Confers
More informationLeft Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
More informationNHS England. Anticoagulation Therapy
NHS England Evidence review: Clinical and Cost- Effectiveness and Adverse Events Associated with Left Atrial Appendage Occlusion in Patients for Whom Anticoagulation Therapy is Contraindicated Anticoagulation
More informationLeft Atrial Appendage Closure: Neurological events
Left Atrial Appendage Closure: Neurological events Medical Director- Foundation for Cardiovascular Medicine San Diego, CA Director Advanced Interventional Therapies- Gagnon Cardiovascular Institute, Morristown,
More informationLeft Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation
Left Atrial Appendage Occlusion: Shutting Out Embolic Disease Without Anticoagulation Zoltan G. Turi, M.D. Rutgers Robert Wood Johnson Medical School New Brunswick, NJ Disclosure Information Zoltan G.
More informationDavid Hildick-Smith, John Camm, Hans-Christoph Diener, Ulf Landmesser, Vincent Paul, Boris Schmidt, Magnus Settergren, Emmanuel Teiger, Claudio Tondo
THE AMULET STUDY: A Multicenter, Prospective Registry of the Amulet Left Atrial Appendage Closure Device for Stroke Prevention in Patients with Atrial Fibrillation David Hildick-Smith, John Camm, Hans-Christoph
More informationLeft atrium appendage closure: A new technique for patients at high hemorrhagic risk
Left atrium appendage closure: A new technique for patients at high hemorrhagic risk Victoria Martin Yuste MD PhD ITC. Cardiology Department. Hospital Clinic. Barcelona SITE. Barcelona, Juin-9-2013 NON
More informationThe Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure?
The Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure? Suneet Mittal, MD, FACC, FHRS Director, Electrophysiology Laboratory Valley Health System Ridgewood, NJ and New York, NY
More informationWatchman a Stroke Prevention Technology for Patients with Atrial Fibrillation
Watchman a Stroke Prevention Technology for Patients with Atrial Fibrillation Scripps hospital,la Jolla, CA Atrial fibrillation is a major source of cardiogenic embolic related stroke 500,000 strokes per
More informationLeft atrial appendage closure with the Amplatzer Cardiac Plug: Rationale for a higher degree of device oversizing at implantation
ORIGINAL ARTICLE Cardiology Journal 2015, Vol. 22, No. 2, 201 205 DOI: 10.5603/CJ.a2014.0063 Copyright 2015 Via Medica ISSN 1897 5593 Left atrial appendage closure with the Amplatzer Cardiac Plug: Rationale
More informationMEDICAL POLICY SUBJECT: PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE DEVICES EFFECTIVE DATE: 08/20/15 REVISED DATE: 10/20/16, 11/16/17
MEDICAL POLICY SUBJECT: PERCUTANEOUS LEFT ATRIAL CATEGORY: Technology assessment PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.
More informationSHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY
SHARED DECISION MAKING: AN EVIDENCE-BASED CORNERSTONE OF LAAC THERAPY SHARED DECISION MAKING: AN EVIDENCE BASED CORNERSTONE OF LAAC THERAPY Shared decision making is a collaborative process that allows
More informationTrick or Treat 2: A New Era of Stroke Prevention in AF? WATCHMAN and LARIAT?
Trick or Treat 2: A New Era of Stroke Prevention in AF? WATCHMAN and LARIAT? Disclosure SentreHeart, Inc Consultant Equity holder A cardiac disease that kills by producing emboli The most severe consequence
More informationAtrial fibrillation (AF) affects approximately 33 million
Emerging Options for Anticoagulation in LAA Closure Managing anticoagulation and antiplatelet therapy in patients undergoing percutaneous left atrial appendage closure with the Watchman device. BY JESSICA
More informationMEDICAL POLICY MEDICAL POLICY DETAILS POLICY STATEMENT POLICY GUIDELINES DESCRIPTION. Page: 1 of 9
Page: 1 of 9 MEDICAL POLICY MEDICAL POLICY DETAILS Medical Policy Title PERCUTANEOUS LEFT ATRIAL APPENDAGE CLOSURE DEVICES Policy Number 7.01.92 Category Technology assessment Effective Date 08/20/15 Revised
More informationUpdate in Left Atrial Appendage Closure Devices. Faisal Al-Samadi MBBS, FRCPC, FACP, FACC, FSCAI, FHRS
Update in Left Atrial Appendage Closure Devices Faisal Al-Samadi MBBS, FRCPC, FACP, FACC, FSCAI, FHRS Atrial Fibrillation - Overview Higher stroke risk for older patients and those with prior stroke or
More informationRESPECT Safety Findings
CO-1 SCAI Town Hall Meeting Monday, October 31, 2016 Washington, DC RESPECT Safety Findings John D. Carroll, M.D., MSCAI Professor of Medicine Cardiology University of Colorado School of Medicine University
More informationAbstract 1 INTRODUCTION ORIGINAL ARTICLE
Received: 5 October 2017 Revised: 2 November 2017 Accepted: 6 November 2017 DOI: 10.1111/jce.13385 ORIGINAL ARTICLE Feasibility of percutaneous left atrial appendage closure using a novel LAmbre occluder
More informationSafety and efficacy results in the EWOLUTION all-comers LAA closure study: DAPT subgroup
Safety and efficacy results in the EWOLUTION all-comers LAA closure study: DAPT subgroup Martin W. Bergmann, Hüseyin Ince, Stephan Kische, Thomas Schmitz, Felix Meincke, Boris Schmidt, David Foley, Timothy
More informationLeft atrial appendage occlusion
Kardiologie Left atrial appendage occlusion Mischa Kühne Kardiolunch, 10.9.2015 Overall stroke rate 5% per year CHA 2 DS 2 VASC score Most AF patients need protection from stroke ESC guidelines AF, 2010/2012
More informationReference: NHS England 1692
Clinical Commissioning Policy Proposition: Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation (Adults) Reference: NHS England
More informationPERCUTANEOUS LEFT ATRIAL APPENDAGE OCCLUSION FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION:
PERCUTANEOUS LEFT ATRIAL APPENDAGE OCCLUSION FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION: Procedural Experience and Clinical Follow-up with the AMPLATZER Cardiac Plug and AMPLATZER Amulet
More informationLeft Atrial Appendage Occlusion in the Era of Novel Anticoagulants
Left Atrial Appendage Occlusion in the Era of Novel Anticoagulants Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac Research Heart Institute, Cedars-Sinai Medical Center,
More informationClinical Data Summary & Discussion Of the Ultraseal Left Atrial Appendage (LAA) Closure Device
Clinical Data Summary & Discussion Of the Ultraseal Left Atrial Appendage (LAA) Closure Device The clinical data used to support the CE marking of the Ultraseal LAA Closure device comes from three sources.
More informationWhat the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen
What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen What the cardiologist should know about arrhythmia and stroke are there real low
More informationMedical Policy Manual. Topic: Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation. Date of Origin: December 2011
Medical Policy Manual Topic: Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Date of Origin: December 2011 Section: Medicine Last Reviewed Date: October 2013 Policy No:
More informationLeft Atrial Appendage Closure 4 questions Who? When? How? Results?
Left Atrial Appendage Closure 4 questions Who? When? How? Results? David R. Holmes, Jr., M.D. Mayo Clinic, Rochester ACC New York CVS New York, NY December 2017 2012 MFMER slide-1 Presenter Disclosure
More informationNHS England Reference: P
Clinical Commissioning Policy: Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation (adults) NHS England Reference: 170060P
More informationPage 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem
Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion Benjamin A. D Souza, MD, FACC, FHRS Assistant Professor of Clinical Medicine Penn Presbyterian Medical Center Cardiac
More informationLeft Atrial Appendage Closure in SCRIPPS CLINIC
Left Atrial Appendage Closure in Atrial Fibrillation to Prevent Stroke Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic La Jolla, CA, USA price.matthew@scrippshealth.org
More informationWatchman and Structural update..the next frontier. Ari Chanda, MD Cardiology Associates of Fredericksburg
Watchman and Structural update..the next frontier Ari Chanda, MD Cardiology Associates of Fredericksburg Different Left Atrial Appendage (LAA) morphologies Watchman (the device) Fabric Anchors Device structure
More informationWATCHMAN PROTECT AF Study Rev. 6
WATCHMAN PROTECT AF Study Rev. 6 Protocol Synopsis Title WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation (PROTECT AF) Sponsor Atritech/Boston Scientific
More informationThessaloniki October 9, Apostolos Tzikas MD, PhD, FESC
7 th IICE Congress Thessaloniki October 9, 2014 Left atrial appendage occlusion with the Amplatzer Amulet: a case report Apostolos Tzikas MD, PhD, FESC Interventional Cardiologist Structural & Congenital
More informationHands on workshops. 08:00-10:15 Session 1 - LAA morphology and imaging Moderator: Saibal Kar, MD / Shakeel A. Qureshi, MD / Bushra Rana, MD
Friday, November 20th, 2015 07:00-18:30 Registration 07:00-08:00 Welcome coffee Hands on workshops 08:00-10:15 Session 1 - LAA morphology and imaging Moderator: Saibal Kar, MD / Shakeel A. Qureshi, MD
More informationΕιδικές ομάδες ασθενών με κολπική μαρμαρυγή. Πρέπει,πως και πότε να χορηγηθεί αντιπηκτική αγωγή
11 ΣΥΝΕΔΡΙΟ ΕΠΕΜΒΑΤΙΚΗΣ ΚΑΡΔΙΟΛΟΓΙΑΣ ΚΑΙ ΗΛΕΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ Ειδικές ομάδες ασθενών με κολπική μαρμαρυγή. Πρέπει,πως και πότε να χορηγηθεί αντιπηκτική αγωγή Χρόνια νεφρική νόσος/αιμοδιύλυση ΣΠΥΡΟΜΗΤΡΟΣ
More informationCommercial Products Percutaneous left atrial appendage closure is considered medically necessary when the criteria above is met.
Medical Coverage Policy Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation EFFECTIVE DATE: 07 01 2016 POLICY LAST UPDATED: 09 04 2018 OVERVIEW Stroke prevention
More informationLeft Atrial Appendage Closure: The Rationale
Left Atrial Appendage Closure: The Rationale JOHN D. HUMMEL, MD DIRECTOR OF CLINCAL ELECTROPHYSIOLOGY RESEARCH PROFESSOR OF CLINICAL INTERNAL MEDICINE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER 1 Disclosures
More informationDevices for Stroke Prevention. Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP
Devices for Stroke Prevention Douglas Ebersole, MD Interventional Cardiology Watson Clinic LLP Overview Left Atrial Appendage Closure FDA Approved Watchman Investigational Amulet PFO Closure Atrial Fibrillation
More informationExclusion de l auricule gauche par voie percutanée
Exclusion de l auricule gauche par voie percutanée Jean-Michel Juliard, Dominique Himbert, Pierre Aubry, Eric Brochet, Alec Vahanian Hôpital Bichat, Paris Pas de conflit d intérêt 2012 The Left Atrial
More informationWatchman Implantation Case Presentation and Discussion
Watchman Implantation Case Presentation and Discussion Walid Saliba, MD, FHRS Director Atrial Fibrillation Center Co-Director AF Stroke Prevention Center Cleveland Clinic Indication FDA NonValvular AF
More informationPercutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Last Review Status/Date: December 2015 Page: 1 of 17 Devices for Stroke Prevention in Atrial Description Stroke prevention in atrial fibrillation is an important consideration. Treatment with anticoagulant
More informationLAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC
LAA Occluders: The Right Device for the Right Patient ACC/SHA MEETING OCTOBER 31 ST 2015 JEDDAH, KSA OMER A. M. ELAMIN, MD, FACC INTERVENTIONAL CARDIOLOGIST DIRECTOR, ADULT CARDIOLOGY FELLOWSHIP TRAINING
More informationLeft Atrial Appendage Closure Andrea Robinson, RN, MSN, ACNP
Left Atrial Appendage Closure Andrea Robinson, RN, MSN, ACNP Cardiac Electrophysiology Nurse Practitioner OhioHealth Heart & Vascular Physicians Riverside Methodist Hospital none Disclosures Atrial Fibrillation
More informationLeft Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD
Left Atrial Appendage Occlusion: A Valid Option to Anticoagulation for Long-term Prevention of Stroke Saibal Kar, MD Director of Interventional Cardiac Research Cedars Sinai Medical Center Disclosure Statement
More informationTechnology Assessment Report No. 302
Technology Assessment Report No. 302 Economic Analysis of Left Atrial Appendage Closure for patients with atrial fibrillation, high stroke risk, and contraindicated to anticoagulants Last updated May 2018
More informationThe evolving role of left atrial appendage occlusion
ORIGINAL ARTICLE 288 A high-volume single-centre experience The evolving role of left atrial appendage occlusion Raffael A. Ghenzi, Slayman Obeid, Francesco Maisano, Maurizio Taramasso, Ronald Binder,
More informationPercutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Section: Medicine Effective Date: October 15, 2016 Last Review Status/Date: September 2016 Page: 1 of 16 Devices for Stroke Prevention in Atrial Description Stroke prevention in atrial fibrillation is
More informationScientific Program of LAA 2014
Scientific Program of LAA 2014 Friday, November 14th, 2014 08:00-18:30 Registration 08:00-08:05 Welcome 08:05-08:45 Session 1: How Morphology Affects Short- and Long-term Outcome? What you Need to Know
More informationPREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation
PREVAIL: 5-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure vs Medical Therapy in Patients With Nonvalvular Atrial Fibrillation Dr. Saibal Kar, MD TCT 2017 Late Breaking Clinical
More informationAppendage Closure. Jason Rogers, MD. Director, Interventional Cardiology UC Davis Medical Center Sacramento, California
Appendage Closure Jason Rogers, MD Director, Interventional Cardiology UC Davis Medical Center Sacramento, California Left Atrium: Atrial Fibrillation Left Atrial Appendage Left Atrium Incidence of Atrial
More informationAtrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
More informationAtrial fibrillation (AF) is a common arrhythmia worldwide
Left Atrial Appendage Closure Under Intracardiac Echocardiographic Guidance: Feasibility and Comparison With Transesophageal Echocardiography Yae Matsuo, MD;* Petr Neuzil, MD, PhD;* Jan Petru, MD; Milan
More informationקוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן
קוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן INTRODUCTION The prevalence of atrial fibrillation (AF) is approximately 1.5 2% of the general population The arrhythmia is associated: with
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationCryptogenic Stroke: A logical approach to a common clinical problem
Cryptogenic Stroke: A logical approach to a common clinical problem Alphonse M. Ambrosia, DO, FACC Interventional Cardiologist CardioVascular Associates of Mesa Mesa, Arizona Speakers Bureau Boston Scientific
More informationPeri-cardioversion and peri-ablation anticoagulation. Giuseppe Patti Campus Bio-Medico University of Rome
Peri-cardioversion and peri-ablation anticoagulation Giuseppe Patti Campus Bio-Medico University of Rome What 2016 ESC guidelines recommend Causes of TE events after cardioversion 1 Preexisting LA thrombosis
More information8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes
8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference 2017 Dubai: 19-21 October 2017 Acute Coronary Syndromes Antonio Colombo Centro Cuore Columbus and S. Raffaele Scientific
More informationLeft atrial appendage closure indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey
Europace (2015) 17, 642 646 doi:10.1093/europace/euv069 EP WIRE Left atrial appendage closure indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey Laurent Pison
More informationWilliam A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, Pennsylvania USA
William A. Gray MD System Chief of Cardiovascular Services, President, Wynnewood, Pennsylvania USA What does Guilty until Effective mean? A fact is a simple statement that everyone believes. It is innocent
More informationIntroduction EP WIRE. ... Keywords
Europace (217), 1 6 doi:1.3/europace/eux254 EP WIRE Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association
More informationLAmbre LAA Occluder Updates
LAmbre LAA Occluder Updates 4 th Asia Pacific Congenital & Structural Interventional Symposium 6 th June, 2013 Hong Kong Yat-yin LAM MBBS MRCP FHKCP FHKAM FESC FRCP FACC MD Associate Professor, Prince
More informationLeft atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives
Review Article Left atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives Bin Kong 1,2, Yu Liu 1,2, He Huang 1,2, Hong Jiang 1,2, Congxin
More informationPercutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Section Medicine
2.02.26 Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Section Medicine Effective Date August 29, 2014 Subsection Cardiology Original Policy Date July 6,
More informationLeft Atrial Appendage Closure: Techniques and Guidelines. Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA
Left Atrial Appendage Closure: Techniques and Guidelines Mohammad Shenasa, MD Heart & Rhythm Medical Group San Jose, CA May is Stroke Awareness Month 2 September is AF Awareness Month Lecture Highlights
More informationICE 2012 Ioannina,
ICE 2012 Ioannina, 15-12-2012 Case presentation Left Atrial Appendage Occlusion therapy for Stroke Prevention in Atrial Fibrillation Apostolos Tzikas MD, PhD, FESC Interventional Cardiology Congenital
More informationUpdate in Left Atrial Appendage Occlusion: More Options
Update in Left Atrial Appendage Occlusion: More Options Sajjad A Sabir, MD Director, Structural Heart Disease Program Director, Interventional Echocardiography Director, Heart Valve Clinic Non-Valvular
More informationPercutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Policy Number: 2.02.26 Last Review: 6/2014 Origination: 1/2012 Next Review: 12/2014 Policy Blue Cross and
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationCARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Title: Reintroduction Overview: Watchman Speaker: Mario Goessl, MD, FACC, FAHA, FESC, FSCAI Minneapolis Heart Institute at Abbott Northwestern Hospital Date: Monday, October 24,
More informationTHINK OUTSIDE THE PILLBOX
THINK OUTSIDE THE PILLBOX An innovative one-time procedure that reduces the risk of stroke in your non-valvular atrial fibrillation (NVAF) patients and the long-term risk of bleeding that comes with a
More informationDepartment of Neurology, Medical University of Silesia, Hospital No. 7, Professor Leszek Giec Upper Silesian Medical Centre, Katowice, Poland
Original paper Percutaneous closure of the left atrial appendage for secondary prevention of stroke in patients with atrial fibrillation and contraindications to chronic anticoagulant therapy Anetta Lasek-Bal
More informationDisclosures 6/16/2015. Preventing Stroke in Atrial Fibrillation Warfarin Intolerance / Non-Compliance
6/16/2015 Data Behind LAA Closure This is Ready for Prime Time! Vivek Y. Reddy, MD Helmsley Trust Professor of Medicine Director, Cardiac Arrhythmia Service The Mount Sinai Hospital vivek.reddy@mountsinai.org
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Percutaneous Left Atrial Appendage Closure Device Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Percutaneous Left Atrial Appendage Closure Devices
More informationManagement of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationCase Report Hemostasis of Left Atrial Appendage Bleed With Lariat Device
273 Case Report Hemostasis of Left Atrial Appendage Bleed With Lariat Device Amena Hussain MD, Muhamed Saric MD, Scott Bernstein MD, Douglas Holmes MD, Larry Chinitz MD NYU Langone Medical Center, United
More informationTHINK OUTSIDE THE PILLBOX
THINK OUTSIDE THE PILLBOX An innovative one-time procedure that reduces the risk of stroke in your non-valvular atrial fibrillation (NVAF) patients and the long-term risk of bleeding that comes with a
More informationAtrial Fibrillation. Atrial Fibrillation
Atrial Fibrillation Stroke and Blood Thinning Medications What else is available? Srinivas Iyengar, MD, FACC, with Boulder Heart Structural Heart Director, Boulder Community Health 303-622-5849 Atrial
More information심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation
소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE
More informationPercutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation
Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationNCVH Birmingham 2013 August 24, Michael S. Bailey, MD Birmingham Heart Clinic
NCVH Birmingham 2013 August 24, 2013 Michael S. Bailey, MD Birmingham Heart Clinic NCVH Birmingham 2015 August 29, 2015 Michael S. Bailey, MD Birmingham Heart Clinic Left Atrial Anatomy Part of a larger
More information